Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)

    NEXT STORY
    RenovaCare Appoints Alan L. Rubino as President and CEO
    PREV STORY
    BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial

    author_avatar
    NASDAQ Market News

    FibroGen Reports First Quarter 2018 Financial Results

    Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase ...

    author_avatar
    NASDAQ Market News

    Novo Nordisk expands its biopharm business with the acquisition of the US and Canadian rights to Macrilen(TM)

    Bagsværd, Denmark, 31 October 2018 ­- Novo Nordisk today announced the expansion of its ...

    author_avatar
    NASDAQ Market News